EUVIMEDEUVIMED entdecken
Crossref

Imaging Pulmonary Fibrosis and Treatment Efficacy In Vivo with Autotaxin-Specific PET Ligand [ 18 F]ATX-1905

Xiaoyun Deng iD, Junyi Liu, Jianyuan Zhou, Yifan Shi, Shuang Song, Jiahui Chen iD, Yinlong Li, Bo Yu, Steven H Liang iD, Xiaohua Zhu iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Xiaoyun Deng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 43…. Hauptthemen laut MEDLINE: Phosphoric Diester Hydrolases, Bleomycin, Pyridones, Indoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by unpredictable progression and limited therapeutic options. Current diagnosis relies on high resolution computed tomography (HRCT), which may not adequately capture early signs of deterioration. The enzyme autotaxin (ATX) emerges as a prominently expressed extracellular secretory enzyme in the lungs of IPF patients. The objective of this study was to evaluate the effectiveness of 18F-labeled ATX-targeted tracer [18F]ATX-1905, in comparison with [18F]FDG, for early fibrosis diagnosis, disease evolution monitoring, and treatment efficacy assessment in bleomycin-induced pulmonary fibrosis (BPF) models. To assess treatment efficacy, mice were treated with two commonly used drugs for IPF, pirfenidone or nintedanib, from Day 9 to Day 23 postbleomycin administration. Lung tissue assessments encompassed inflammation severity via H&E staining, and Ashcroft scoring via Masson staining, alongside quantification of ATX expression through ELISA. Positron emission tomography (PET) imaging employing [18F]FDG and [18F]ATX-1905 tracked disease progression pre- and post-treatment. The extent of pulmonary fibrosis corresponded to changes in ATX expression levels in the BPF mouse model. Notably, [18F]ATX-1905 exhibited elevated uptake in BPF lungs during the progression of the disease, particularly evident at the early stage (Day 9). This uptake was inhibited by an ATX inhibitor, PF-8380, underscoring the specificity of the radiotracer. Conversely, [18F]FDG uptake, peaking at Day 15, decreased subsequently, likely reflective of diminished inflammation. A 2-week treatment regimen using either pirfenidone or nintedanib resulted in notable reductions of ATX expression levels and fibrosis degrees within lung tissues, based on ELISA and Masson staining, as evidenced by PET imaging with [18F]ATX-1905. [18F]FDG uptake also decreased following the treatment period. Additionally, PET/CT imaging extended to a nonhuman primate (NHP) BPF model. The uptake of [18F]ATX-1905 (SUVmax = 2.2) was significantly higher than that of [18F]FDG (SUVmax = 0.7) in fibrotic lung tissue. Using our novel ATX-specific radiotracer [18F]ATX-1905 and PET/CT imaging, we demonstrated excellent ability in early fibrosis detection, disease monitoring, and treatment assessment within lungs of the BPF mouse models. [18F]ATX-1905 displayed remarkable specificity for ATX expression and high sensitivity for ATX alterations, suggesting its potential for monitoring varying ATX expression in lungs of IPF patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphoric Diester HydrolasesBleomycinPyridonesIndolesFluorodeoxyglucose F18Positron-Emission TomographyAnimalsMiceLungIdiopathic Pulmonary FibrosisDisease Models, AnimalPulmonary FibrosisMice, Inbred C57BLFluorine RadioisotopesRadiopharmaceuticalsMaleTreatment OutcomePositron Emission Tomography Computed TomographyLysophospholipase D

Stichwörter der Autor:innen

[18F]ATX-1905autotaxinpositron emission tomographypulmonary fibrosis

Substanzen

Phosphoric Diester HydrolasesBleomycinPyridonesIndolesFluorodeoxyglucose F18Fluorine RadioisotopesRadiopharmaceuticalsLysophospholipase Dnintedanibpirfenidone

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, China.
  • Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia 30322, United States.

ORCID-Profile: Xiaoyun Deng, Jiahui Chen, Steven H Liang, Xiaohua Zhu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Deng, X., Liu, J., Zhou, J., Shi, Y., Song, S., Chen, J., Li, Y., Yu, B., Liang, S. H., & Zhu, X. (2024). Imaging Pulmonary Fibrosis and Treatment Efficacy In Vivo with Autotaxin-Specific PET Ligand [ 18 F]ATX-1905. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00571

Vancouver

Deng X, Liu J, Zhou J, Shi Y, Song S, Chen J, et al. Imaging Pulmonary Fibrosis and Treatment Efficacy In Vivo with Autotaxin-Specific PET Ligand [ 18 F]ATX-1905. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00571

BibTeX
@article{Deng2024,
  author = {Deng, Xiaoyun and Liu, Junyi and Zhou, Jianyuan and Shi, Yifan and Song, Shuang and Chen, Jiahui and Li, Yinlong and Yu, Bo and Liang, Steven H and Zhu, Xiaohua},
  title = {Imaging Pulmonary Fibrosis and Treatment Efficacy In Vivo with Autotaxin-Specific PET Ligand [ 18 F]ATX-1905},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00571}
}
Kostenlos starten →